Jose Baselga

Summary

Publications

  1. doi request reprint Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Clin Cancer Res 16:4876-83. 2010
  2. doi request reprint Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, Barcelona 08035, Spain
    Nat Rev Cancer 9:463-75. 2009
  3. ncbi request reprint Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting
    Pablo Matar
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 10:6487-501. 2004
  4. doi request reprint A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers
    Josep Lluís Parra-Palau
    Statistics Department, Faculty of Biology, Vall d Hebron Institute of Oncology, University of Barcelona, Barcelona, Spain
    Cancer Res 70:8537-46. 2010
  5. pmc RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
    Violeta Serra
    Experimental Therapeutics, Vall d Hebron Institute of Oncology, Barcelona, Spain
    J Clin Invest 123:2551-63. 2013
  6. pmc Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Maurizio Scaltriti
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2688-95. 2010
  7. ncbi request reprint Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    Maurizio Scaltriti
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital and Research Institute, Barcelona 08035, Spain
    J Natl Cancer Inst 99:628-38. 2007
  8. doi request reprint NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
  9. ncbi request reprint Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
    Jose Baselga
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron 119 129 08035 Barcelona, Spain
    J Clin Oncol 23:5323-33. 2005
  10. ncbi request reprint 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis
    Federico Rojo
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 13:81-9. 2007

Detail Information

Publications49

  1. doi request reprint Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Clin Cancer Res 16:4876-83. 2010
    ..Tumor biopsy samples were taken to investigate the effect of saracatinib on Src activity in tumors...
  2. doi request reprint Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, Barcelona 08035, Spain
    Nat Rev Cancer 9:463-75. 2009
    ..These new therapies include tyrosine kinase inhibitors, antibody-chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2-ERBB3 dimers...
  3. ncbi request reprint Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting
    Pablo Matar
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 10:6487-501. 2004
    ....
  4. doi request reprint A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers
    Josep Lluís Parra-Palau
    Statistics Department, Faculty of Biology, Vall d Hebron Institute of Oncology, University of Barcelona, Barcelona, Spain
    Cancer Res 70:8537-46. 2010
    ..2%). These results reveal a mechanism of ER regulation mediated by HER2, which suggests a new strategy to improve responses to endocrine therapy in breast cancer...
  5. pmc RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
    Violeta Serra
    Experimental Therapeutics, Vall d Hebron Institute of Oncology, Barcelona, Spain
    J Clin Invest 123:2551-63. 2013
    ..These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK...
  6. pmc Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Maurizio Scaltriti
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2688-95. 2010
    ..We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting...
  7. ncbi request reprint Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    Maurizio Scaltriti
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital and Research Institute, Barcelona 08035, Spain
    J Natl Cancer Inst 99:628-38. 2007
    ....
  8. doi request reprint NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  9. ncbi request reprint Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
    Jose Baselga
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron 119 129 08035 Barcelona, Spain
    J Clin Oncol 23:5323-33. 2005
    ..To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer...
  10. ncbi request reprint 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis
    Federico Rojo
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 13:81-9. 2007
    ....
  11. doi request reprint Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy
    Celina García-García
    Department of Experimental Therapeutics Laboratory, Vall d Hebron Institute of Oncology, Pg Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 18:2603-12. 2012
    ..The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance...
  12. doi request reprint USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
    Pieter J A Eichhorn
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Nat Med 18:429-35. 2012
    ..Our results show that USP15 regulates the TGF-β pathway and is a key factor in glioblastoma pathogenesis...
  13. ncbi request reprint Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
    Emiliano Calvo
    Vall d Hebron University Hospital, Universidad Autonoma de Barcelona, Barcelona, Spain
    J Clin Oncol 24:2158-63. 2006
    ..Therefore, in clinical trials with tyrosine kinase inhibitors and other molecular-targeted therapies, the inclusion of a global population appears to be required...
  14. doi request reprint Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
    Jose Baselga
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    J Clin Oncol 27:2630-7. 2009
    ..This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001)...
  15. pmc A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis
    Kim Pedersen
    Medical Oncology Research Program, Vall d Hebron University Hospital, Psg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Mol Cell Biol 29:3319-31. 2009
    ..These results demonstrate that 611-CTF is a potent oncogene capable of promoting mammary tumor progression and metastasis...
  16. doi request reprint Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:307-14. 2009
    ....
  17. doi request reprint Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib
    Susana Cedres
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Lung Cancer 66:257-61. 2009
    ..Inhibition of the EGFR pathway is a useful strategy in the treatment of patients with advanced NSCLC. The aim of this study is to assess predictive clinical parameters of efficacy...
  18. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
    ..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
  19. pmc Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
    Maurizio Scaltriti
    Departments of Medical Oncology and Molecular Pathology, Vall d Hebron Institute of Oncology, 08035 Barcelona, Spain
    Proc Natl Acad Sci U S A 108:3761-6. 2011
    ....
  20. doi request reprint Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona, Spain E 08035
    J Clin Oncol 28:1138-44. 2010
    ..This phase II trial assessed the efficacy and safety profile of the combination in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy...
  21. doi request reprint Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 27:526-34. 2009
    ..Gene expression studies were undertaken using genes that were identified as potentially associated with sensitivity/resistance to ixabepilone in prior preclinical investigations...
  22. ncbi request reprint ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
    Judit Anido
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Clin Cancer Res 9:1274-83. 2003
    ..Our aim was to explore the effects of ZD1839 in breast cancer cell lines expressing different levels of EGFR and the closely related HER2 receptor...
  23. ncbi request reprint Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    Federico Rojo
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 24:4309-16. 2006
    ..The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study...
  24. pmc HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation
    Jesús García-Castillo
    Medical Oncology Research Program, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Biol Chem 284:25302-13. 2009
    ..These results suggest that cortactin is a target of 611-CTF involved in the regulation of cell migration and, thus, in the metastatic behavior of breast tumors expressing this CTF...
  25. doi request reprint Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 28:1181-9. 2010
    ....
  26. ncbi request reprint Targeting tyrosine kinases in cancer: the second wave
    Jose Baselga
    Oncology Program, Vall d Hebron University Hospital and Vall d Hebron Research Institute, Universidad Autonoma de Barcelona, Barcelona 08035, Spain
    Science 312:1175-8. 2006
    ..Agents directed against new molecular targets are also being explored...
  27. doi request reprint Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
    Teresa Macarulla
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 9:2844-52. 2010
    ..Pharmacodynamic analyses in mitotic cells of both skin and tumor provided proof of mechanism for Aurora A kinase inhibition. A more potent, selective, second-generation Aurora A kinase inhibitor, MLN8237, is in clinical development...
  28. doi request reprint Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
    Maurizio Scaltriti
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Mol Cancer Ther 10:817-24. 2011
    ..IPI-504-mediated Hsp90 inhibition may represent a novel therapeutic approach in trastuzumab refractory HER2-positive breast cancer...
  29. ncbi request reprint 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications
    Gemma Armengol
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 67:7551-5. 2007
    ..Further investigation into this concept may identify additional funnel factors in the oncogenic pathways and provide potential therapeutic targets...
  30. ncbi request reprint Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and n
    Jose Baselga
    Vall d Hebron University Hospital, Oncology Service, P Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 23:5568-77. 2005
    ....
  31. doi request reprint A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012
    ..A phase I study was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), establish a safety profile, and to evaluate pharmacokinetics and efficacy of the drug...
  32. doi request reprint Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
    Serena Di Cosimo
    Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:5017-9. 2009
    ..These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway...
  33. doi request reprint Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]
    Serena Di Cosimo
    Breast Cancer Center, Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 7:139-47. 2010
    ..Thus, the overall management of breast cancer will increasingly require an understanding of breast cancer heterogeneicity, the biological nature of any given tumor as well the existence of increased personalized treatment options...
  34. doi request reprint A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    Enriqueta Felip
    Medical Oncology Service and Pathology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 14:3867-74. 2008
    ..To examine potential markers of clinical benefit and the effects of erlotinib on the epidermal growth factor receptor (EGFR) signaling pathway in advanced non-small cell lung cancer patients refractory to platinum-based chemotherapy...
  35. ncbi request reprint Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Oncology Service, Barcelona, Spain
    Oncologist 11:4-12. 2006
    ..Overall, results from clinical trials are sufficiently compelling to consider 1 year of adjuvant trastuzumab treatment for women with HER-2-positive EBC based on the risk:benefit ratio demonstrated in these studies...
  36. ncbi request reprint Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer
    Josep Castellvi
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer 107:1801-11. 2006
    ....
  37. doi request reprint Targeted therapies in breast cancer: where are we now?
    Serena Di Cosimo
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital, Passeig Vall d Hebron, Barcelona, Spain
    Eur J Cancer 44:2781-90. 2008
    ..We will present these novel therapies and will analyse for each target the developmental status of some of the agents as well as target-specific challenges...
  38. doi request reprint Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, corrected Barcelona, Spain
    J Clin Oncol 26:1603-10. 2008
    ..In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors...
  39. ncbi request reprint Epidermal growth factor receptor pathway inhibitors
    Jose Baselga
    Medical Oncology Service, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Cancer Chemother Biol Response Modif 22:205-23. 2005
  40. doi request reprint CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Breast Cancer 10:489-91. 2010
    ..Combining trastuzumab and pertuzumab therefore provides a more comprehensive blockade of the HER signaling pathways, resulting in greater antitumor efficacy...
  41. doi request reprint Molecular prescreening to select patient population in early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Spain
    Nat Rev Clin Oncol 9:359-66. 2012
    ....
  42. doi request reprint Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors
    Andres Cervantes
    Hematology and Medical Oncology Department, Hospital Clinico, INCLIVA, University of Valencia, Valencia, Spain
    Clin Cancer Res 18:4764-74. 2012
    ..This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors...
  43. ncbi request reprint Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
    Jose Baselga
    Medical Oncology Service, Vall d Hebron Research Institute and Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 23:2445-59. 2005
    ....
  44. ncbi request reprint TGF-beta signalling-related markers in cancer patients with bone metastasis
    Jose Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    Biomarkers 13:217-36. 2008
    ..PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-beta inhibitor...
  45. doi request reprint Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence
    Pier Davide Angelini
    Preclinical Research, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer Res 73:450-8. 2013
    ..Underscoring the functional relevance of the p95HER2-induced senescence secretome, we show that p95HER2-induced senescent cells promote metastasis in vivo in a non-cell-autonomous manner...
  46. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    J Clin Oncol 23:2521-33. 2005
    ....
  47. ncbi request reprint Targeting the microtubules in breast cancer beyond taxanes: the epothilones
    Javier Cortes
    Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 12:271-80. 2007
    ..The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer...
  48. doi request reprint TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma
    Judit Anido
    Vall d Hebron Institute of Oncology, Barcelona, Spain
    Cancer Cell 18:655-68. 2010
    ..High CD44 and Id1 levels confer poor prognosis in GBM patients...
  49. ncbi request reprint Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
    Joan Albanell
    Oncology Service, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 20:110-24. 2002
    ..We studied the pharmacodynamic effects of ZD1839 on EGFR in the skin, an EGFR-dependent tissue, in cancer patients participating in ZD1839 phase I clinical trials...